OncoZenge AB stock analysis
OncoZenge AB (8LY) Stock Price & Analysis
8LY Stock Chart & Stats
- Day’s Range
- EUR 0.28 - EUR 0.28
- 52-Week Range
- EUR 0.23 - EUR 0.63
- Previous Close
- EUR 0.28
- Volume
- N/A
- Average Volume (3M)
- 0
- Market Cap
- EUR 8.07M
- Enterprise Value
- EUR 108.32M
- Total Cash (Recent Filing)
- EUR 24.30M
- Total Debt (Recent Filing)
- EUR 0
- Price to Earnings (P/E)
- ―
- Beta
- 0.71
- Next Earnings
- Feb 18, 2027 (Est.)
- EPS Estimate
- N/A
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Debt-Free Balance Sheet
The current debt-free position and positive equity provide financial flexibility while the company develops its oncology products. Low leverage reduces interest burden and refinancing pressure, giving management more room to allocate capital toward commercialization and operational needs.
Solid Gross Margin
A gross margin near 68% indicates that the product economics can retain a meaningful portion of revenue after direct costs. If revenue recovers and operating spending becomes more disciplined, this underlying margin profile could support improved contribution toward fixed costs and eventual profitability.
Focused Oncology Supportive Care
The focused product strategy targets a specific unmet supportive-care need in oncology rather than pursuing a broad pharmaceutical portfolio. Concentration on severe cancer pain and treatment-related oral mucositis can help align development and commercialization resources around a defined clinical application.
Bears Say
Persistent Cash Burn
Materially negative operating and free cash flow show that the business is not yet funding itself from operations. Continued cash burn can require additional financing or a rapid improvement in revenue and costs, potentially limiting strategic flexibility over the coming quarters.
Revenue Volatility
The sharp decline in revenue highlights limited consistency in the current commercial base. Unstable sales make it harder to forecast cash generation, plan investment, or spread operating costs efficiently, leaving the company more exposed until demand and commercialization become more dependable.
Deep Operating Losses
The scale of operating and net losses shows that current revenue is far below the level needed to cover the cost base. Even with a solid gross margin, sustained losses can consume equity and require significant improvement in sales productivity or expense discipline to reach breakeven.
OncoZenge AB News
8LY FAQ
What was OncoZenge AB’s price range in the past 12 months?
What is OncoZenge AB’s market cap?
When is OncoZenge AB’s upcoming earnings report date?
How were OncoZenge AB’s earnings last quarter?
Is OncoZenge AB overvalued?
Does OncoZenge AB pay dividends?
What is OncoZenge AB’s EPS estimate?
How many shares outstanding does OncoZenge AB have?
What happened to OncoZenge AB’s price movement after its last earnings report?
Which hedge fund is a major shareholder of OncoZenge AB?
What is the TipRanks Smart Score and how is it calculated?
Company Description
OncoZenge AB
OncoZenge AB (publ) operates as a pharmaceutical company with a focus on developing medical solutions that offer supportive care for cancer patients. A significant product in its pipeline is BupiZenge, which has successfully completed Phase 2 clinical trials for the management of oral mucositis. This company was established in 2020 and conducts its operations from its headquarters in Bromma, Sweden. Notably, OncoZenge AB (publ) is a subsidiary entity of Moberg Pharma AB (publ).
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Stian Kildal
- Employees
- 1
- Website
- www.oncozenge.se
- Address
- Gustavslundsvagen 34, Bromma, AB, 167 51, SE
OncoZenge AB (8LY) Earnings & Revenues
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 8 | 3 | 10 |
| Technical Analysis | 2 | 3 | 4 |
| Moving Averages | 6 | 0 | 6 |


